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Betty T. Tran,1,2 Abigail Halperin,3 Jason W. Chien1,2Abnormal lung function is a known risk factor for poor outcomes in the allogeneic hematopoietic stem cell
transplantation (HSCT) population, although the specific causes of these abnormalities have not been well
explored. There is limited data on the effect of cigarette smoking on transplantation outcomes. We con-
ducted a retrospective observational cohort study of 845 consecutive patients age $18 years who under-
went allogeneic HSCT at the Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center.
Smoking exposure was defined by quit time, smoking status (never, former, and current), and log2-trans-
formed pack-years. The main outcomes were time to respiratory failure within 100 days of transplantation,
relapse, and nonrelapse mortality. In multivariable analyses, a 2-fold increase in pack-years smoked was as-
sociated with an increased risk of early respiratory failure (hazard ratio [HR] 1.33, 95% confidence interval
[CI] 1.09 to 1.64, P5 .006). This association was observed independent of pretransplantation lung function.
A 2-fold increase in pack-years smoked was associated with an increased risk of relapse, but this finding was
not statistically significant (HR 1.16, 95% CI 0.92-1.46, P 5 .21). An association was not observed between
cigarette smoking and nonrelapse mortality. Cigarette smoking is associated with an increased risk of respi-
ratory failure and relapse within 100 days of allogeneic HSCT. The association with respiratory failure is me-
diated in part by abnormal lung function before transplantation and likely through other mechanisms as well.
Given the adverse effects associated with cigarette smoking before transplantation, future studies should fo-
cus on obtaining accurate smoking histories, tracking prospective changes in smoking status, and assessing
the benefits of tobacco cessation on outcomes in this population.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) has become standard therapy to treat a variety
of malignant and other hematologic diseases, with
over 20,000 allogeneic transplantations performed an-
nually worldwide [1]. Despite its widespread use,
transplantation-related mortality and morbidity remain
high. The 100-day mortality rate for allogeneic trans-
plantations ranges from 10% to 40% [2]. In addition,
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Pulmonary complications account for most of the life-
threatening conditions that develop posttransplanta-
tion, and traditionally, are classified as early or late
depending on whether they occur before or after day
100.
Prior studies have suggested that abnormal pretrans-
plant pulmonary function tests (PFTs) increase the risk of
complications, including early respiratory failure and
mortality [4-7]. Causes for abnormal pretransplantation
lung function, however, have not been well explored.
Cigarette smoking is known to be a primary cause of
abnormal PFTs [8,9], and previous studies have
reported that 14% to 62% of transplantation candidates
have a former or current history of smoking [10-13].
Cigarette smoking, therefore, may account for some of
the abnormal PFTs observed before transplantation,
but there are limited data on the direct effects of
cigarette smoking on early pulmonary complications,
relapse, and mortality posttransplantation. Marks et al.
[12] reported that ‘‘high-dose’’ smoking, defined by
$10 pack-year history and smoking $1 pack per day,
was associated with an increased risk of treatment-
related mortality and disease relapse. Some studies have
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tions among smokers, whereas others have not demon-
strated such associations [11,13]. In general, these
studies have been limited by small numbers of patients
or have focused on only certain transplantation
populations. Furthermore, despite growing evidence
that cigarette smoking impairs immune function,
exacerbates cancer treatment-related toxicities, and in-
creases risk of recurrence and secondary malignancies,
few clinical oncology studies collect information on
smokinghistoryunless themalignancy is primarily smok-
ing related [14-17]. Given these limitations, we
conducted a retrospective observational cohort study to
assess the relationship between pretransplantation
cigarette smoking and early respiratory failure, relapse,
and posttransplantation nonrelapse mortality (NRM)
among adult allogeneic HSCT recipients.METHODS
Patient Selection
All adult patients (age $18 years) who received an
allogeneic HSCT at Fred Hutchinson Cancer Re-
search Center between June 20, 2005, and June 30,
2009, were eligible for the study (n 5 846). On June
20, 2005, routine tracking of smoking history began
during pretransplantation pulmonary function testing.
Cigarette Smoking
Cigarette smoking was the primary exposure.
Smoking history was obtained via self-report during
pretransplantation pulmonary function testing and
categorized as never, former, or current. For this
study, we defined a former smoker as an individual
who quit smoking for at least 1 year before the inter-
view. Patients who were currently smoking or had
quit for\1 year before the interview were considered
current smokers. Smoking dose was defined in pack-
years (number of cigarettes smoked per day/20 multi-
plied by years smoked) and log2-transformed to
achieve a normal distribution.
Outcomes Assessment
The primary outcomes were respiratory failure
within 100 days, disease relapse, and NRM. Early re-
spiratory failure was defined as mechanical ventilation
for a nonelective reason within 100 days after trans-
plantation. Because the majority of our patients are
discharged from our center after 100 days, this time
period provides the most complete and accurate respi-
ratory failure data [7]. For patients who had multiple
episodes of respiratory failure within 100 days, only
the time to the first respiratory failure episode was
analyzed. NRM was defined as mortality without
evidence of disease relapse.Covariates
Datawerecollectedonpatientdemographics, includ-
ing age, gender, and race.Disease riskwas defined as low,
intermediate, or high risk for mortality as described by
Parimon and colleagues [18]. Low-risk diseases include
chronic myelogenous leukemia (CML) in chronic phase,
refractory anemia, and aplastic anemia. Intermediate-risk
diseases include CML in accelerated phase or chronic
phase after blast phase, acute leukemia or lymphoma in
remission, refractory anemia with excess blasts, and
chronic lymphocytic leukemia. High-risk diseases in-
clude chronicmyelogenous leukemia inblast phase, acute
leukemia, or lymphoma in relapse,myeloma, solid tumor,
and nonhematologic diseases. Pertinent data were also
collected to calculate a Pretransplant Assessment ofMor-
tality (PAM) score as previously described [18].
Stem cell sources were classified as bone marrow,
peripheralbloodstemcell (PBSC), cordblood,or a com-
bination of bone marrow and PBSC. Donor match
status was determined according to donor-recipient
human leukocyte antigen (HLA) compatibility. Condi-
tioning regimens were categorized as myeloablative or
nonmyeloablative.Myeloablative regimenswere further
grouped according to the dose of total-body irradiation
used: none, #12 Gy, or .12 Gy. Cytomegalovirus
(CMV) serologic status was assessed in both recipient
and donor. Acute graft-versus-host disease (aGVHD)
was graded I-IV, and categorized as ‘‘no’’ (grades 0-II)
or ‘‘yes’’ (grades III-V) based on stages of organ involve-
ment using standard criteria [19,20]. Chronic GVHD
(cGVHD) was defined by the National Institutes of
Health (NIH) 2005 criteria [21].
Pulmonary function testing was obtained routinely
before transplantation and again approximately 80 to
120 days posttransplantation. All pulmonary function
tests were performed at the FredHutchinsonCancer Re-
search Center according to American Thoracic Society
guidelines [22]. All pulmonary function values, except
the ratio of forced expiratory volume in 1 second
(FEV1) to forced vital capacity (FVC), were expressed
as apercentageof predicted values according topublished
equations [23,24], unless otherwise specified. Diffusing
capacity for carbon monoxide (DLCO) measurements
were corrected for hemoglobin levels obtained at the
closest time to the DLCO measurement [25].Statistical Methods
All statistical analyses were performed using
STATA 11.0 (StataCorp, College Station, TX). Base-
line variables were compared between smoking groups
usingPearson chi-square testingor t tests for continuous
variables. Time-to-event analyses were conducted using
Cox proportional hazards regressionmodels to estimate
the hazard ratios (HRs) for associations between
pretransplantation smoking and transplantation out-
comes. Huber-White standard errors were used to
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secondary analyses,weused linear regression to examine
the association between smoking dose and days 80 to
120 pulmonary function. The multivariable model
included smoking status as a categoric variable and
log2-transformed pack-years. We decided a priori to
also include age, gender, and conditioning regimen as
potential confounders. Additional covariates, including
patient race, disease risk, CMV status, stem cell source,
donor HLA match, PAM score, and aGVHD and
cGVHDmodeled as time-varying covariates, were eval-
uated independently in the models and included in the
final adjusted models based on likelihood ratio testing.
Measures of pulmonary function were then added to
themultivariablemodel.OnlyFEV1 andDLCOwere in-
cluded in these models because of the high correlation
among FEV1, FVC, total lung capacity (TLC), and
the lack of correlation betweenDLCOand the other pul-
monary function parameters [7]. Two-sided P values
\.05 were considered statistically significant.
Data for each patient were censored at the time of
the event of interest, death, or date of last contact, which-
ever came first, with the exception of analyses involving
early respiratory failure, where patients were censored
at 100 days if they did not have the outcome or died. In
analyses involving nonrelapse mortality and relapse,
these outcomes were considered competing events and
censored accordingly. Data for 1 patient was censored
at 83 days at the time of a second transplantation.RESULTS
FromJuly20,2005, to June30,2009,846patientsun-
derwent allogeneicHSCT.One patient was excluded for
missing smoking data. Clinical characteristics are sum-
marized in Table 1. There were 230 former smokers
(27%)and85current smokers (10%).Theoverallmedian
number of pack-years smokedwas 10 (interquartile range
[IQR] 4-25). The median number of days before trans-
plantation that a smoking history was obtained was 24
days (IQR 20-35 days). The median age was 58 years
(IQR 51-63 years) in former smokers and 46 years
(IQR 32-57 years) in current smokers compared with
50 years (IQR 38-59 years) in never smokers. This is
slightly older than in previous studies and reflects the
trend of increasing numbers of allogeneic transplanta-
tions among individuals older than 50 years of age
[10-13,26]. Former smokers were more likely to receive
a nonmyeloablative conditioning regimen, consistent
with older age in this group. Although the majority of
transplantation patients at our institution undergo
bronchoscopy for evaluation of acute radiographic
abnormalities, specific pulmonary infections are difficult
to identify in this cohort because the majority of
patients are already taking broad-spectrum antibiotic
and antifungal therapy before bronchoscopy. Neverthe-less, therewasno significantdifference in the rateofbron-
choscopies performed in never smokers versus former or
current smokers. There were no significant differences
with regard to patient gender, ethnicity, underlying dis-
ease severity, donor HLA match, CMV status, and stem
cell source between the groups.
PFTs, including spirometry and DLCO, were ob-
tained on 96% of patients before transplantation. Over
75% of patients in all 3 smoking groups had normal
FEV1, FVC, and TLC percent predicted values (Table
2). Both former and current smokers had slightly lower
FEV1 and FEV1/FVC compared to never smokers. A
greater proportion of current smokers had DLCO values
that were\80%.
Smoking and Early Respiratory Failure
Early respiratory failure occurred in 32 (6%) never
smokers, 14 (6%) former smokers, and 2 (2%) current
smokers. The median number of days after transplanta-
tion to respiratory failure was 17.5 days (IQR 11-29.5
days). Forty-four of the 48 patients (92%) died after re-
ceivingmechanical ventilation. Themain reasons for re-
spiratory failure included acute respiratory distress
syndrome (ARDS)/acute lung injury (ALI) (n 5 15,
31%), aspiration/mucositis (n5 11, 23%), diffuse alveo-
lar hemorrhage (n5 8, 17%), and idiopathic pneumonia
syndrome (n 5 7, 14%), as defined by previous criteria
[27-29]. In multivariable analyses adjusting for age, sex,
conditioning regimen, smoking status, and aGVHD,
smoking dose, defined in pack-years, was associated
with a higher risk of early respiratory failure. For each
doubling of pack-years, theHR for early respiratory fail-
ure increased 33% (95% confidence interval [CI] 1.09 to
1.64, P5 0.006) (Figure 1).
Figure 2 shows the projected cumulative incidence
curves, using our model for early respiratory failure,
with all HSCT predictors being equal except smoking
dose. In this projection, we combined former and
current smokers into 1 group and compared a never-
smokingpatient to a smokerwith a 20 pack-year history
and another smoker with a 40 pack-year history.
To better understand how abnormal pulmonary
function may have accounted for the association
between pretransplantation smoking and early respira-
tory failure, we then included pretransplantation pul-
monary function in the multivariable model. As
expected, the addition of variables for pulmonary func-
tion attenuated ourHR for early respiratory failure, but
an association between the 2-fold increase in pack-
years and risk of early respiratory failure remained
(HR 1.25, 95% CI 1.02-1.55, P5 0.03) (Figure 1).
Smoking and Relapse
One hundred sixty-two of the patients relapsed, in-
cluding 105 (20%) never smokers, 42 (18%) former
smokers, and 15 (18%) current smokers, with a median
Table 1. Patient Characteristics
Characteristic Never Smokers (n 5 530) (%) Former Smokers (n 5 230) (%) Current Smokers (n 5 85) (%) P value
Age (years) <.0005
median (IQR) 50 (38-59) 58 (51-63) 46 (32-57)
Male 302 (57) 138 (60) 47 (55) .67
Caucasian race 456 (89) 205 (92) 77 (93) .81
Pack-years
median (IQR) — 10 (4-20) 15 (6-30) .05
Donor HLA status .68
Related/matched 191 (36) 86 (37) 30 (35)
Related/mismatched 27 (5) 13 (6) 8 (9)
Unrelated/matched 204 (39) 80 (35) 27 (32)
Unrelated/mismatched 107 (20) 51 (22) 20 (24)
Disease risk .35
Low 41 (8) 11 (5) 7 (8)
Intermediate 299 (56) 146 (63) 48 (57)
High 190 (36) 73 (32) 30 (35)
Conditioning regimen .001
Nonmyeloablative 204 (38) 123 (53) 25 (29)
Myeloablative
Non-TBI 170 (32) 55 (24) 37 (44)
TBI #12 Gy 132 (25) 47 (20) 19 (22)
TBI >12 Gy 20 (4) 5 (2) 3 (3)
Stem cell source .75
Bone marrow 75 (14) 30 (13) 14 (16)
PBSC 420 (79) 190 (83) 67 (79)
BM, PBSC 3 (1) 0 0
Cord 32 (6) 10 (4) 4 (5)
CMV (recipient/donor) .27
neg/neg 149 (30) 67 (30) 27 (33)
neg/pos 57 (12) 19 (9) 4 (5)
pos/neg 140 (28) 77 (35) 27 (33)
pos/pos 151 (30) 56 (26) 23 (29)
Acute GVHD 73 (14) 27 (12) 11 (13) .74
Chronic GVHD 218 (52) 93 (54) 22 (32) .005
Bronchoscopy performed 99 (19) 52 (23) 17 (20) .46
IQR indicates interquartile range; TBI, total-body irridiation; PBSC, peripheral blood stem cell; BM, bone marrow; CMV, cytomegalovirus; GVHD,
graft-versus-host disease.
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(IQR 71-239 days). Over three-quarters of those who
relapsed (78%) died. In multivariable analyses adjust-
ing for age, gender, conditioning regimen, smoking
status, disease risk, donor HLA type, and aGVHD
and cGVHD (as time-varying covariates), a 2-fold in-
crease in pack-years was associated with a higher risk of
relapse, but this finding was not statistically significant
(HR 1.16, 95% CI 0.92 to 1.46, P 5 .21) (Figure 1).Smoking and NRM
There were 386 (46%) deaths from all causes in
this cohort. Of these, 127 had relapsed, leaving 259
(31%) individuals (156 [37%] never smokers, 79
[42%] former smokers, 24 [34%] current smokers)
with NRM. The median number of days after trans-
plantation to NRM was 163 days (IQR 62-298 days).
In multivariable analyses adjusting for age, gender,conditioning regimen, smoking status, donor HLA
type, PAM score, stem cell source, and aGVHD and
cGVHD, smoking dose was not associated with
a higher risk of NRM (HR 0.97, 95% CI 0.85-1.10,
P 5 .64) (Figure 1).
Smoking and Day 100 Pulmonary Function
We performed secondary analyses of the relation-
ship between smoking dose and pulmonary function
obtained routinely 80 to 120 days posttransplantation.
After adjustment for patient age, gender, conditioning
regimen, and smoking status, smoking dose was not
significantly associated with changes in FEV1, FVC,
TLC, or DLCO from baseline (data not shown).
Stratification by Donor Type
Because prior studies have cited differential trans-
plantation outcomes with HLA-identical sibling
Table 2. Distribution of Pretransplant Pulmonary Function Tests
PFT Parameter
Never Smokers
(n 5 530) (%)
Former Smokers
(n 5 230) (%)
Current Smokers
(n 5 85) (%) P value
Percent predicted FEV1 .04
$80% 434 (82) 180 (78) 66 (78)
70-79% 52 (10) 27 (12) 9 (11)
60-69% 16 (3) 10 (4) 3 (4)
<60% 9 (2) 7 (3) 4 (5)
Percent predicted FVC .57
$80% 456 (86) 202 (88) 74 (87)
70-79% 39 (7) 17 (7) 7 (8)
60-69% 9 (2) 4 (2) 0
<60% 7 (1) 1 (0.5) 1 (1)
FEV1/FVC
median (IQR) 0.77 (0.73-0.82) 0.75 (0.70-0.79) 0.73 (0.68-0.79) <.0005
Percent predicted TLC .21
$80% 477 (90) 213 (93) 77 (91)
70-79% 20 (4) 8 (3) 4 (5)
60-69% 5 (1) 0 0
<60% 7 (1) 1 (0.5) 0
Percent predicted DLCO .0009
$80% 216 (41) 95 (41) 23 (27)
70-79% 169 (32) 67 (29) 24 (28)
60-69% 92 (17) 38 (16) 21 (25)
<60% 37 (7) 25 (11) 14 (16)
IQR indicates interquartile range; TLC, total lung capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing
capacity for carbon monoxide; PFT, pulmonary function test.
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analyzed the association between cigarette smoking
and transplantation outcomes separately for these sub-
groups. After adjustment, there was still an increased
risk of early respiratory failure with a 2-fold increase
in pack-years in both groups. Patients who received
an HLA-identical related transplant had an 83% in-
creased risk of early respiratory failure (95% CI 1.18
to 2.84, P 5 .007) compared with a 46% increased
risk among patients receiving an unrelated matched
transplant (95% CI 1.02-2.09, P 5 .04) (Table 3).
Smoking dose was associated with an increased risk
of relapse in patients receiving an unrelated matched
transplant (HR 1.44, 95% CI 1.04-2.01, P 5 .03).
There was a weak association between pack-years
and relapse in related matched donor transplants that
was not significant (HR 1.21, 95% CI 0.92-1.60, P 5
.17). Smoking dose was again not associated with
NRM when stratified by donor type (Table 3).DISCUSSION
The major finding of our study is that lifetime
smoking dose is associated with an increased risk of
respiratory failure within 100 days of transplant. This
relationship appears to be only partially mediated by
pretransplant lung function, suggesting that other
biological mechanisms may be involved. We did not
observe significant effects of smoking on overall re-lapse or NRM, although the direction of the associa-
tion between smoking dose and relapse warrants
further investigation.
Few studies have examined whether cigarette
smoking is a risk factor for poor transplantation out-
comes, and those have had conflicting results. Ho
et al. [11] found that smoking history, measured by
smoking status (never, current, quit .1 year) was not
associated with increased risk for early severe pulmo-
nary complications, defined as diffuse alveolar hemor-
rhage, need for mechanical ventilation, or death from
respiratory failure within the first 60 days posttrans-
plantation. In contrast, a study done by Savani and col-
leagues [13] reported that a history of smoking was
associated with a 5-fold increase in the risk of
transplantation-related mortality from pulmonary
causes. The latter, however, had a smaller cohort (n
5 146), included patients diagnosed with idiopathic
pneumonia syndrome, and followed patients for a me-
dian of 3.6 years. The largest study by Marks et al.
[12], with 2818 patients who received allogeneic trans-
plants for CML in the first chronic phase, found that
the risk of treatment-related mortality was 57% higher
among $10 pack-year smokers compared with never
smokers. In addition, such a smoking history was asso-
ciated with an increased risk of disease relapse, a find-
ing consistent with a prior study by Chang et al.
[10,12]. These findings, however, were observed only
in recipients of HLA-identical sibling donor trans-
plants [12].
Figure 1. Multivariable adjusted hazards ratios for the association between cigarette smoking and early respiratory failure, relapse, and NRM.
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atedwith smoking, althoughmainly among patients re-
ceiving an unrelated matched HSCT. These results
should be considered preliminary, although in light
of studies demonstrating that smoking increases the
risk of hematologic malignancies, this may be biologi-
cally plausible [30,31]. The.2-fold increase in relapse
risk among recipients of unrelated matched donors in
our study may be partly attributable to our cohort
having a higher underlying disease risk; we includedFigure 2. Projected cumulative incidence curves for early respiratory
failure associated with never smoking versus 20 pack-year smoking
history versus 40 pack-year smoking history.a variety of underlying diseases that warranted
allogeneic transplantation as opposed to the cohorts
in the Chang and Marks studies, which focused on
CML in a stable phase. Unlike the study by Marks
et al., we did not find an association between smoking
and NRM, despite observing that 92% of patients
who were placed on mechanical ventilation in the first
100 days after transplantation ultimately died. It isTable 3. Multivariable Adjusted HRs for the Association be-
tween Smoking and Early Respiratory Failure, Relapse, or
Nonrelapse Mortality, Stratified by Donor HLAType
Outcome N (%) HR 95% CI P value
Related matched donor 307 (36%)
Early respiratory failure* 1.83 1.18 to 2.84 .007
Relapse† 1.21 0.92 to 1.60 .17
Nonrelapse mortality‡ 0.99 0.77 to 1.29 .97
Unrelated matched donor 311 (37%)
Early respiratory failure* 1.46 1.02 to 2.09 .04
Relapse† 1.44 1.04 to 2.01 .03
Nonrelapse mortality‡ 0.91 0.74 to 1.12 .38
HR indicates hazard ratio; CI, confidence interval; GVHD, graft-versus-
host disease.
*Adjusted for age, gender, smoking status, conditioning regimen, acute
GVHD.
†Adjusted for age, gender, smoking status, conditioning regimen, disease
risk, acute and chronic GVHD.
‡Adjusted for age, gender, smoking status, conditioning regimen, stem
cell source, PAM score, acute and chronic GVHD.
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chose to forego mechanical ventilation before death.
Alternatively, it is possible that smoking is not a risk
factor for other common causes of non-relapsemortal-
ity such as aGVHDor cGVHDand nonpulmonary or-
gan toxicity or failure. There are several possible
mechanisms for the association between smoking
dose and early respiratory failure. Pretransplantation
PFTs are reportedly important predictors of early
posttransplantation pulmonary complications and
mortality [5-7]. These parameters likely represent
markers of previous lung injury and worse health
status before transplantation. In addition, cigarette
smoking has immunomodulatory effects that have
been linked to increased susceptibility to infection.
The alveolar macrophages found in the lungs of
smokers, for example, have a reduced ability to
phagocytose bacteria and are known to secrete lower
levels of inflammatory cytokines necessary for up-
regulation of host defenses [32,33]. Cigarette smoke
may also have independent effects on mucociliary
clearance and alterations in surfactant proteins [34-38].
The strengths of our study include a large cohort,
availability of detailed smoking history, and availability
of PFTs near transplantation. There are, however, im-
portant limitations to consider when interpreting our
results. First, social desirability, especially before an
upcoming transplantation, may have led to underre-
porting of smoking. Although we do not have reason
to believe this bias is differential among those who ex-
perienced respiratory failure or died, the effect would
tend to bias ourHRs toward the null. Second, we could
not assess whether smoking was continued or resumed
during the posttransplantation period, whichmay have
affected our outcomes. Third, although there are no
firm exclusion criteria with regard to PFTs, smoking
status, or pulmonary disease for transplantation eligi-
bility at our center, patients with severe pulmonary
and other comorbidities may never have made it to
transplantation; thus, there could be selection bias.
Despite these limitations, the findings that: (1) the
vast majority of patients undergoing transplantation
have normal lung function, including former and cur-
rent smokers (Table 2), and (2) an association remains
between smoking dose and early respiratory failure in-
dependent of lung function, lends credence to our con-
clusion that cigarette smoking, even in patients
without serious comorbidities or compromised lung
function, has independent deleterious effects after
transplantation.
In summary, our study found a significant associa-
tion between cigarette smoking and respiratory failure
within 100 days of transplantation. This finding ap-
pears to be only partially mediated by abnormal lung
function before transplantation. Although we found
no significant association between smoking and relapse
or NRM after allogeneic HSCT, a trend was apparent,and future prospective studies with longer-term
outcomes and ongoing monitoring of smoking status
are warranted to explore this issue.We are not suggest-
ing that HSCT should be withheld or delayed in
patients with a smoking history in need of transplanta-
tion; however, because cigarette smoking identifies in-
dividuals at increased risk of early morbidity
posttransplantation, they should be counseled accord-
ingly. Given the prevalence of smoking among HSCT
cohorts, further studies should focus on tobacco cessa-
tion efforts in this patient population. In addition, they
should evaluate the potential impact of length of quit
time among former smokers and recent quitters on al-
logeneic transplantation outcomes, as this could iden-
tify a window of opportunity for aggressive tobacco
cessation interventions. This study also emphasizes
the need for routine inclusion of smoking status and
a more detailed smoking history both before and after
transplantation in future HSCT studies.ACKNOWLEDGMENTS
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